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Previous in vitro studies identified secreted frizzled related protein 1 (SFRP1) as a candidate pro-proliferative signal during prostatic
development and cancer progression. This study determined the in vivo roles of SFRP1 in the prostate using expression studies in mice and by
creating loss- and gain-of-function mouse genetic models. Expression studies using an Sfrp1lacZ knock-in allele showed that Sfrp1 is expressed in
the developing mesenchyme/stroma of the prostate. Nevertheless, Sfrp1 null prostates exhibited multiple prostatic developmental defects in the
epithelium including reduced branching morphogenesis, delayed proliferation, and increased expression of genes encoding prostate-specific
secretory proteins. Interestingly, over-expression of SFRP1 in the adult prostates of transgenic mice yielded opposite effects including prolonged
epithelial proliferation and decreased expression of genes encoding secretory proteins. These data demonstrated a previously unrecognized role for
Sfrp1 as a stromal-to-epithelial paracrine modulator of epithelial growth, branching morphogenesis, and epithelial gene expression. To clarify the
mechanism of SFRP1 action in the prostate, the response of WNT signaling pathways to SFRP1 was examined. Forced expression of SFRP1 in
prostatic epithelial cells did not alter canonical WNT/β-catenin signaling or the activation of CamKII. However, forced expression of SFRP1 led to
sustained activation of JNK, and inhibition of JNK activity blocked the SFRP1-induced proliferation of prostatic epithelial cells, suggesting that
SFRP1 acts through the non-canonical WNT/JNK pathway in the prostate.
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doi:10.1016/j.ydbio.2008.02.021ductal–acinar gland residing at the base of the bladder (Marker
et al., 2003). The prostate is also the site of two common male
diseases, benign prostatic hyperplasia (BPH) and prostate
cancer that arise in distinct anatomic regions of the prostate
(McNeal, 1983). The organization of both the developing and
adult prostate includes two tissue layers, the prostatic epithe-
lium and a supporting mesenchyme/stroma. During develop-
ment, reciprocal cell–cell signaling between the epithelium and
the surrounding developmental mesenchyme coordinates sev-
eral developmental processes, while in the adult reciprocal cell–
cell signaling between the prostatic epithelium and surrounding
stroma maintain gland architecture and function. In recent years,
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signaling is an important part of cancer progression in the
prostatic epithelium (Cunha et al., 2004).
Following an earlier study demonstrating that fibroblasts
isolated from prostatic adenocarcinomas could promote prostate
cancer progression in adjacent epithelia (Olumi et al., 1999), we
identified secreted frizzled related protein 1 (SFRP1) as a
candidate stromal-to-epithelial paracrine signaling molecule
over-expressed by cultured fibroblasts isolated from adenocar-
cinomas relative to cultured fibroblasts isolated from benign
prostates (Joesting et al., 2005). Further evaluation of SFRP1
expression using real-time RT-PCR in developing mouse
prostates and in cultured human cell lines demonstrated that
expression levels paralleled prostatic growth rates with high
expression during developmental growth, low expression in
normal adult mouse prostate, and high expression in tumorigenic
prostatic cell lines and cultured fibroblasts from prostatic adeno-
carcinomas. Forced expression of SFRP1 also increased proli-
feration in non-tumorigenic human prostatic epithelial cell lines.
Collectively, these in vitro data identified SFRP1 as a candidate
pro-proliferative stromal-to-epithelial paracrine signal during
prostatic development and cancer progression. However, the
status and functional roles of SFRP1 in the prostate in vivo
remained untested.
In the mouse, prostatic development begins during late fetal
stages, but most developmental growth, branching morphogen-
esis, and cellular differentiation occur between birth and repro-
ductive maturity at approximately 5 weeks after birth. The
prostate develops from the urogenital sinus (UGS), which arises
by embryonic day 13 (e13) and remains morphologically ambi-
sexual until around e17.5. At that time, androgen initiated and
androgen dependent prostatic morphogenesis begins with the
outgrowth of epithelial buds from the urogenital sinus epithe-
lium (UGE) into the surrounding urogenital sinus mesenchyme
(UGM). The epithelium initially invades the surrounding me-
senchyme as solid epithelial cords that elongate within the
UGM, bifurcate, and produce ductal side-branches to create a
complex branched network of prostatic ducts (Risbridger et al.,
2005; Sugimura et al., 1986). Branching morphogenesis is
largely complete by 2 weeks after birth and ultimately gives rise
to 3–4 bilaterally symmetrical prostatic lobes, each harboring a
unique pattern of ductal branching (Hayward et al., 1996;
Marker et al., 2003; Sugimura et al., 1986). During the initial
phase of prostatic development, both the UGM and UGE are
composed of undifferentiated cells. The epithelial cells forming
the initial buds and elongating cords that invade the UGM co-
express genes that later become restricted to specific differ-
entiated cell types including cytokeratins 5, 8, 14, and 18 as well
as p63 (Wang et al., 2001). As the epithelial cords mature into
ducts containing a lumen, most epithelial cells differentiate into
either luminal epithelial cells that express cytokeratins 8 and 18
or basal epithelial cells that express cytokeratins 5 and 14 as
well as p63. Several minor epithelial cell populations are also
present in maturing prostatic ducts including neuroendocrine
cells, postulated transit amplifying cells, and candidate stem
cells. As the prostate approaches reproductive maturity from 3–
5 weeks after birth, luminal epithelial cells initiate expression ofandrogen-induced secretory proteins in a region-restricted man-
ner in the adult prostate gland (Thielen et al., 2007).
Many years of genetic and experimental embryologic studies
have investigated the roles of androgen signaling and epithelial–
mesenchymal interactions in prostatic development. Androgens
are necessary and sufficient to specify the UGS as prostate. This
is shown by the absence of a prostate in Tfm mice that lack
functional androgen receptors, and by the induction of a prostate
in female UGSs treated with androgens (Brown et al., 1988;
Cunha, 1975; He et al., 1994; Takeda et al., 1986) Experiments
utilizing recombinant grafts of UGE and UGM from wild type
and Tfm mice demonstrated the requirement for androgen
receptor expression in the UGM, and not the UGE for prostatic
bud induction and branching morphogenesis (Cunha and Lung,
1978; Donjacour and Cunha, 1993). These data led to the theory
that one or more factors act in a paracrine fashion to stimulate
prostatic development in the UGE. Several candidate paracrine
factors expressed in the UGM such as FGF10 (Donjacour et al.,
2003) and BMP4 (Lamm et al., 2001) have been investigated for
their roles in prostatic development. However, known paracrine
signals do not yet explain all of the paracrine interactions that
have been inferred from experimental embryological studies.
The initial data for Sfrp1 in the prostate (Joesting et al., 2005)
raised the possibility that it may also act as a paracrine regulator
of epithelial development in the prostate.
Sfrp1 is one of 5 structurally related genes that encode
secreted proteins homologous to the Frizzled receptors for
WNT ligands (Rattner et al., 1997). SFRP1 has been reported to
bindWNT ligands and modulate their signaling activity (Dennis
et al., 1999; Uren et al., 2000). Expression studies using in situ
hybridization demonstrated strong Sfrp1 expression at devel-
opmental time points in the mouse kidney, heart, salivary gland,
bone, teeth, and brain (Bodine et al., 2004; Esteve et al., 2003;
Garcia-Hoyos et al., 2004; Jaspard et al., 2000; Leimeister et al.,
1998). Despite this broad expression, experiments utilizing
Sfrp1 knockout mice have thus far revealed more anatomically
restricted phenotypes in the developing bone (Bodine et al.,
2004). In addition, experiments using double knockout mice for
both Sfrp1 and Sfrp2 demonstrated a crucial but redundant role
for these genes during early embryogenesis (Satoh et al., 2006).
These previous studies did not report a detailed analysis of
prostatic development in Sfrp1 knockout mice.
In the present study, the roles of SFRP1 in the prostate were
determined through expression studies and by creating loss- and
gain-of-function mouse models. Sfrp1 was expressed in the
developing mesenchyme of the mouse prostate. Sfrp1 loss-of-
function mutants exhibited multiple prostatic developmental
defects including reduced branching morphogenesis, delayed
proliferation, and increased expression of genes encoding pros-
tate-specific secretory proteins while gain-of-function trans-
genics gave opposite effects including prolonged epithelial pro-
liferation and decreased expression of genes encoding secretory
proteins. Forced expression of SFRP1 in cultured prostatic epi-
thelial cells also led to sustained activation of JNK that was
essential for SFRP1-induced epithelial proliferation, suggesting
that SFRP1 acts through the non-canonical WNT/JNK pathway
in prostatic epithelial cells.
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Generation of Sfrp1 mutant mice
The Sfrp1 targeting vector was derived from a genomic clone containing the
first exon that had been isolated from a lambda 129SV library. The short arm of
the targeting vector was a 1.1 kb DNA fragment corresponding to genomic
sequence immediately upstream from the ATG start codon of the Sfrp1 gene.
This element was generated by PCR using primer SFRPA2 (5′-TCTTGAGTTG-
GTATCCACCCAC-3′), which marked the 5′ end of the arm, and primer
SFRPA1 (5′-ATACGGTTGCTCGGCGACGTC-3′), located just in front of the
start codon. The Sfrp1 exon 1 coding sequence immediately downstream from
the ATG was replaced with a LacZ/Neo selection cassette. The long arm was a
12.5 kb genomic fragment which began at the KpnI site of Sfrp1 intron 1 and
extended beyond the RV site to the end of the lambda clone.
Ten micrograms of targeting vector was linearized by NotI digest and
introduced into 129/Sv embryonic stem cells by electroporation. After selection
in G418, surviving colonies were expanded and PCR analysis performed to
identify clones that had undergone homologous recombination. PCR was
conducted using primer SFRPA4 (5′-TGGGGGAGGCTAGAGGACGAC-3′),
corresponding to sequence 100 bp upstream of the short arm, and primer LZ1 (5′-
CGATTAAGTTGGGTAACGCCAGG-3′), located within the LacZ gene,
approximately 100 bp from its 5′-end. Positive clones yielded the expected
1.3 kb fragment. Correctly targeted ES cells were microinjected into C57BL/6J
host blastocysts. Chimeric mice were generated that provided germline trans-
mission of the disrupted Sfrp1 gene. Mice carrying the targeted allele were mated
with C57BL/6J mice, yielding offspring with a mixed genetic background.
LacZ staining
Beta-galactosidase activity in whole embryos was examined as previously
described (Whiting et al., 1991). X-gal stained embryos were post-fixed in 4%
paraformaldehyde, washed in PBS, and processed in a glycerol series to 80%
glycerol for photography and storage. Whole embryos were photographed on a
Leica MZFLIII stereoscope. For analysis of postnatal prostate development,
prostates were harvested from p1–p21 animals. Tissues were fixed in 4% para-
formaldehyde, rinsed in PBS, and incubated in 1 mg/mL X-gal stain overnight at
37 °C. Tissues were dehydrated in graded isopropanol solutions, pre-infiltrated in
a paraffin/isopropanol (1:1) solution, infiltrated in paraffin, and embedded in
paraffin wax. 6 μm sections of paraffin-embedded tissues were cut and mounted
on Superfrost-plus microscope slides (Fisher). Sections were dewaxed in CitriSolv
and rehydrated in a series of graded alcohols and PBS. Sections were stained with
hematoxylin, dehydrated in graded alcohol solutions, and mounted in Permount.
Urogenital sinus microdissection, reverse transcription, and real-time
PCR
Embryos of CD-1 mice (Charles River) were obtained at embryonic day 16.5
and the urogenital sinuses were dissected into Hank’s Buffered Salt Solution
(HBSS) at 4 °C. The urogenital sinus mesenchyme and epithelium were
separated by digestion with 1% trypsin in HBSS for 90 min at 4 °C followed by
manual dissection. Tissues were homogenized in Trizol reagent (Invitrogen) and
RNA was isolated according to the manufacturer’s instructions. Reverse
transcription and real-time RT-PCR reactions were conducted as previously
described (Thielen et al., 2007) on 1 μg of DNAse-treated total RNA. Relative
expression values were calculated as 2−dCt where dCt= the experimental gene Ct
value minus the control gene Ct value.
Generation of PB-SFRP1 transgenic mice
A full-length human SFRP1 cDNA (Finch et al., 1997) was cloned into a
plasmid downstream of the ARR2PB version of the rat probasin promoter
(Zhang et al., 2000). The transgenic fragment was purified by cesium chloride
gradient and isolated from the plasmid backbone by restriction enzyme digestion
and gel electrophoresis. The purified transgene was microinjected into the
pronuclei of single-celled FVB/N embryos by the University of Minnesota
Mouse Genetics Laboratory to establish founder lines.Histology and immunostaining
Prostates were dissected into 4 °C PBS. Tissues were fixed in 10% buffered
formalin, dehydrated, and embedded in paraffin wax. Using a microtome, 6 μm
sections of paraffin-embedded tissues were cut and mounted on Superfrost-plus
microscope slides (Fisher). Sections were dewaxed in CitriSolv and rehydrated
in a series of graded alcohols and PBS. For histological analysis, sections were
stained with hematoxylin and eosin, dehydrated in graded alcohol solutions, and
mounted in Permount. For immunostaining, sections were boiled 30 min in
Antigen Unmasking Solution according to manufacturer’s instructions (Vector
Laboratories, Inc.). Endogenous peroxidase activity was blocked in 3%
hydrogen peroxide and non-specific binding was blocked with 2.5% sheep
serum in PBS. All of the following steps used 2.5% sheep serum as a dilutent or
an M.O.M. kit according to manufacturer’s instructions for antibodies raised in
mice (Vector Laboratories, Inc.). Sections were incubated with primary
antibodies overnight at 4 °C. Mouse monoclonal anti-Ki67 antibody was
used at a 1:100 dilution (Novocastra). After washing in PBT (pH 7.4, 138 mM
NaCl, 2.7 mM KCl, 0.1% Tween 20), sections were incubated in biotinylated
species-specific anti-IgG secondary antibody (Vector Laboratories, Inc.) at a
1:500 dilution and washed in PBT. Tissues were incubated in an avidin–HRP
complex according to manufacturer’s instructions (ABC kit; Vector Labora-
tories, Inc.), washed in PBT, rinsed in PBS, and developed 1–20 min using 3,
3ʺ-diaminobenzidine and hydrogen peroxide according to manufacturer’s
instructions (DAB substrate kit; Vector Laboratories, Inc.). Sections were rinsed
in water, counterstained with hematoxylin, dehydrated in graded alcohol
solutions, and mounted in Permount. Control sections containing no primary
antibody were processed in parallel. Labeling indexes were calculated by
counting the number of positively stained epithelial cells in a minimum total of
500 cells.
Protein extractions
Cells were collected, washed in PBS, and pelleted by centrifugation at
2000 rpm in a tabletop centrifuge. The supernatant was aspirated and the cells
were resuspended in Iso-Hi buffer consisting of 10 mM Tris–HCl, 140 mM
NaCl, 1.5 mM MgCl2, and 0.5% NP-40 to lyse the cell membrane leaving the
nuclei intact. The cell suspension was incubated on ice and processed by
centrifugation at 5000 rpm to pellet the nuclei. The cytoplasmic fraction was
separated from the pelleted nuclei. Nuclei were resuspended and lysed in a high
salt buffer containing 20 mMHEPES, 1 M NaCl, 0.2 mM EDTA, 20% glycerol,
1.5 mM MgCl2, and 0.1 mM EGTA. Total proteins were extracted using a
modified RIPAs buffer containing protease inhibitors and phosphatase
inhibitors.
Western blotting
Proteins were separated by SDS-PAGE and electro-blotted to an Immobilon
membrane (Millipore). Non-specific binding sites were blocked with 1% non-
fat milk powder (Fig. 1) or 1% BSA (Figs. 7 and 8) in TBS (pH 7.4,0.9% NaCl,
20 mM Tris HCl). Membranes were incubated in primary rabbit polyclonal
anti-SFRP1 (Fig. 1, Santa Cruz Biotechnology), goat polyclonal anti-SFRP1
(Fig. 7, R&D Systems), rabbit polyclonal anti-phosphorylated-JNK (#9251) or
anti-phosphorylated-CamKII (#3361) antibody diluted to 1:1000 overnight at
4 °C (Cell Signaling Technology). After washing in TBS containing 1%
Tween-20 (TBST), membranes were incubated in biotinylated anti-rabbit IgG
antibody (Vector Laboratories) at a 1:10,000 dilution, washed in TBST, and
incubated in an avidin–HRP complex according to manufacturer’s instructions
(ABC kit; Vector Laboratories). Membranes were washed in TBST, rinsed in
TBS, and incubated 5 min in an enhanced chemiluminescence reagent (Bio-
Rad) before exposing to film. Membranes were rinsed and subsequently re-
blotted with anti-actin (Santa Cruz), anti-JNK (#9252 Cell Signaling
Technologies) or anti-CamKII (#3362 Cell Signaling Technologies) as
respective loading controls. Activation of the JNK or CamKII pathway was
calculated by normalizing the amount of phosphorylated protein to the amount
of total protein with the aid of the Bio-Rad Molecular Analyst software’s
Densitometer program. Four independent protein extracts were obtained and
analyzed.
Fig. 1. Creation of an Sfrp1lacZ knock-in allele that is null for Sfrp1 function. Sequence immediately downstream of the Sfrp1 start codon in exon 1 and upstream of the
KpnI site in intron 1 was replaced with a LacZ/Neo cassette using homologous recombination in mouse embryonic stem (ES) cells. A schematic diagram of the wild
type (WT) and Sfrp1lacZ knock-in allele (Sfrp1lacZ) shows the genomic structure of the knock-in allele (A). The locations of exon 1 and restriction sites in the modified
region of Sfrp1 are indicated. ES cells harboring the Sfrp1lacZ knock-in allele were used to generate chimeric founder mice that passed the allele to their progeny. The
progeny from intercrossing Sfrp1lacZ heterozygous mice were genotyped using a multiplex PCR system in which wild type primers amplified a 369 bp sequence from
exon 1 and mutant-specific primers produced an amplicon of 480 bp from the LacZ-Neo insert. Genotyping cross progeny identified all possible genotypic classes
among viable cross progeny including wild type (Sfrp1 +/+), heterozygous (Sfrp1 +/−), and homozygous mutant (Sfrp1 −/−) progeny (B). RNA was isolated from
kidneys of female (F) and male (M) cross progeny and real time RT-PCR was performed to determine relative expression levels of Sfrp1 among the 3 genotypic classes
with the transcript for Tata binding protein serving as an internal control. Homozygous Sfrp1lacZmice (−/−) lacked Sfrp1 transcripts containing sequence from exons 1
and 2, consistent with the removal of exon 1 by homologous recombination (C, upper graph). Sfrp1 primers corresponding to exons 2 and 3 which were not removed
by homologous recombination were also used in real time RT-PCR experiments. There was a dramatically reduced level of RNA containing exon 2 and 3 sequence in
homozygous Sfrp1lacZ mice (C, lower graph). Immuno-blots with an anti-SFRP1 antibody confirmed the presence of SFRP1 protein in extracts from the male
reproductive tract glands (prostate + seminal vesicles) of wild type (+/+) but not homozygous Sfrp1lacZmutant (−/−) mice (D, arrowhead in upper panel). An anti-actin
antibody was used as a loading control for the immuno-blot (D, lower panel).
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SFRP1-expressing and empty vector harboring BPH1 cell lines were
generated as previously described (Joesting et al., 2005). Cells were cultured in
RPMI 1640 media (#22400 Gibco) containing 25 mmol/L HEPES, L-glutamine,
5% charcoal-stripped fetal bovine serum, 10 units penicillin, 10 μg/mL strep-
tomycin, 25 μg/mL amphotecirin, and 1×10−8 mol/L testosterone. Cells were
grown in a 5% CO2, 37 °C incubator. Cells were cultured in 4 well culture slides
(#354114 BD Falcon) for 48 h during treatments in media only, media and 0.1%
DMSO (vehicle for SP600125), or media and 10 μmol/L Jun N-terminal kinase
inhibitor SP600125 (#PHZ1264 Invitrogen). After 48 h, cultures were term-
inated by a 2 min incubation in 100% ethanol at −20 °C and air dried. Cells from
terminated cultures were rehydrated with PBS and nonspecific binding sites
were blocked with 2.5% sheep serum in PBS. Cells were incubated in 7 μg/mL
primary anti-phospho-histone-H3 antibody overnight at 4 °C (#06-570 Upstate
Cell Signaling Solutions). Cells were then washed with PBT, and incubated in
biotinylated rabbit anti-IgG antibody (BA-1000, Vector Laboratories) at a 1:500
dilution. Cells were washed with PBT and developed using the avidin–biotin
complex (ABC) (PK-6100, Vector Laboratories) and 3,3′-diaminobezidine(DAB) substrate (SK-4100) kits according to manufacturer’s instructions. Cells
were rinsed in water, counterstained with hematoxylin and dehydrated via
graded ethanol solutions. Control sections containing no primary antibody were
processed in parallel. Pictures were taken in triplicate of cells from each SFRP1-
overexpressing, empty vector-harboring and from the parental BPH1 cell line
grown in each media type. Stained and total cell numbers were counted for each.
Results
Creation of an Sfrp1lacZ knock-in allele
To investigate the importance of Sfrp1 in vivo, the mouse
Sfrp1 locus was modified using homologous recombination in
embryonic stem cells (see Materials and methods). The resulting
mutant allele of Sfrp1 (Sfrp1lacZ allele) had the coding sequences
for β-galactosidase inserted into the first exon of the Sfrp1 gene
(Fig. 1A). Mice homozygous for this mutant allele were viable
Fig. 2. Expression analysis using an Sfrp1lacZ knock-in allele. Staining Sfrp1lacZ
heterozygous embryos for β-galactosidase activity (blue–green stain) revealed
expression patterns created by endogenous Sfrp1 regulatory elements during
development. β-Galactosidase activity was detected at low levels in the extra-
embryonic yolk sac (ys) and the neural plate (np) in the 3 somite stage embryo
(A). At the 9 somite stage, expression was restricted to anterior embryonic
regions. Strong β-galactosidase activity was found in the ventral optic cup (oc),
hindbrain (hb) and spinal cord (sc), while weak activity was detected in the
extraembryonic allantois (a) (B). β-Galactosidase was strongly expressed in the
CNS at E9.5, and was primarily localized to ventral regions, particularly in the
spinal cord (sc) (C). Expression was detected in the midbrain (mb), eye (e) and
forebrain (fb). Strong expression was also detected in the lateral plate and ventral
hindgut (hg) (C). Dorsal view of the same embryo shown in panel B demon-
strating that β-galactosidase was expressed primarily in ventral domains of the
hindbrain (D). Whole mount prostates were also stained for β-galactosidase,
sectioned, and counter-stained with hematoxylin (purple–grey stain). β-
Galactosidase staining was observed in the developing mesenchyme/stroma
(str) and absent from the developing epithelium (epi) in postnatal day 21
prostates (E). A wild type littermate prostate was also stained and counter-
stained as a negative control for any potential background β-galactosidase
staining (F). Panels E and F are from the anterior prostate. A similar staining
pattern was also observed in the other prostatic lobes.
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null for Sfrp1 mRNA expression (Fig. 1C) and SFRP1 protein
expression (Fig. 1D), but in the heterozygous state the Sfrp1lacZ
allele created no discernable phenotype other than expression of
β-galactosidase in the pattern created by endogenous Sfrp1
regulatory elements. A previous study created a different null
allele for Sfrp1 and reported that Sfrp1 null mice had changes in
osteoblast activity that resulted in altered trabecular bone
formation (Bodine et al., 2004). Although we did not undertake
an investigation of bone formation in Sfrp1lacZ mice, we did
provide Sfrp1lacZ mice to another laboratory conducting studies
of bone formation, and they observed similar findings in mice
homozygous for the Sfrp1lacZ allele to those reported by Bodine
et al. for the other Sfrp1 null allele (Matthew Gillespie, personal
communication of unpublished studies).
Expression analysis during mouse development using an
Sfrp1lacZ knock-in allele
Staining Sfrp1lacZ heterozygous embryos for β-galactosidase
activity revealed expression patterns created by endogenous
Sfrp1 regulatory elements during development. At the 3-somite
stage low levels of Sfrp1lacZ gene expression were detectable in
the extra-embryonic yolk sac and in the neural plate (Fig. 2A). In
the 9-somite stage embryo, Sfrp1lacZ expression was strong in
the ventral optic cup, hindbrain, and spinal cord and weak ex-
pression was detectable in the extraembryonic allantois (Figs.
2B, D). Further analysis revealed that Sfrp1lacZ expression was
strong in the central nervous system at embryonic day 9.5 and
was localized mainly to the ventral regions. β-Galactosidase
activity was also strong in the lateral plate and the ventral
hindgut (Fig. 2C). These sites of expression include anatomical
locations that have previously been reported to express Sfrp1
based on in situ hybridization studies (Leimeister et al., 1998) as
well as expression at anatomical locations not previously ex-
amined for Sfrp1 expression.
After confirming that the β-galactosidase reporter recapitu-
lated previously reported expression domains of Sfrp1 expres-
sion during embryonic development, the reporter was used to
evaluate Sfrp1 expression in the developing prostate gland from
postnatal day 1 (p1) to p21. At all stages examined, Sfrp1lacZ
expression was observed in the developing prostatic mesench-
yme/stroma although expression was not observed in all regions
of stroma within the prostate (Fig. 2E and data not shown). At
some developmental stages, β-galactosidase activity was also
observed in limited regions of the prostatic epithelium of
Sfrp1lacZ heterozygous mice, but similar staining was observed
in wild type control embryos at the same stages so this staining
may or may not have reflected expression patterns generated by
endogenous Sfrp1 regulatory elements (data not shown).
It was somewhat surprising that prostatic expression of the β-
galactosidase reporter was predominantly mesenchymal because
we had previously observed both strong epithelial and
mesenchymal expression in the postnatal day 1 rat prostate by
in situ hybridization (Joesting et al., 2005). In the mouse
prostate, we did attempt to detect mouse Sfrp1 transcripts at
several points during mouse prostatic development by in situhybridization using antisense RNA experimental probes and
sense strand RNA probes as a negative control. Although several
probes were tried, the signal for experimental probes did not
significantly exceed the signal for sense control probes sug-
gesting that this technique was not sufficiently sensitive to detect
the Sfrp1 transcripts that were detectable in the mouse prostate
by RT-PCR (data not shown). As an alternative approach to
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endogenous expression of Sfrp1, we separated the urogentital
sinus mesenchyme (UGM) from the urogenital sinus epithelium
(UGE) and examined expression of Sfrp1 and control genes in
the UGM and UGE by real-time RT-PCR. As was suggested by
the β-galactosidase reporter, expression of the endogenous
mouse Sfrp1 gene was predominantly in the developing mesen-
chyme (Fig. 3).
Sfrp1 is required for normal levels of prostatic branching
morphogenesis
The Sfrp1lacZ allele was also used to evaluate the requirement
for Sfrp1 function during prostatic development. Consistent
with previous studies that independently created Sfrp1 null
alleles in mice (Bodine et al., 2004; Satoh et al., 2006), mice
homozygous for the Sfrp1lacZ null allele were born in the ex-
pectedMendelian ratio on a mixed genetic background and were
viable into adulthood. They were also fertile and lacked obvious
external anatomical abnormalities. The previous studies using
other strains of Sfrp1 null mice did not report a detailed exam-
ination of the prostate gland for developmental defects. As an
initial assessment of potential prostatic phenotypes in Sfrp1 null
mice, we examined male mice at sexual maturity (5 weeks old).
At the level of gross morphology, prostates from Sfrp1 null mice
appeared to have normal morphology for all lobes (data not
shown). Despite appearing normal at a gross level, micro-
dissection revealed a significant reduction in the number of distal
tips in each prostatic lobe of the Sfrp1 null mice indicating a
reduced amount of developmental branching morphogenesis
(Fig. 4).
Loss of Sfrp1 delays puberty-associated epithelial cell
proliferation
To further examine the potential role of Sfrp1 in the prostate,
relative proliferation rates in Sfrp1 null and littermate control
prostates were determined using immunohistochemistry (IHC)
to detect Ki67, a cellular proliferation marker (Scholzen andFig. 3. Mouse Sfrp1 is primarily expressed in the prostatic mesenchyme. Urogenital
epithelium from the mesenchyme. Total RNAwas isolated from the urogenital sinus m
time RT-PCR. Control genes with known mesenchyme-specific and epithelial-specific
As expected, mesenchyme-specific gene vimentin was highly expressed in the UGM
highly expressed in the UGE relative to the UGM (B). The expression of Sfrp1 was
depict relative expression as the ratio of the transcript to the 18S ribosomal RNA as
standard deviation.Gerdes, 2000). At 5 weeks of age, Sfrp1 null prostates had
significantly fewer proliferating cells than their wild type litter-
mates (Figs. 5A–C). At 7 weeks of age, Sfrp1 null prostates,
although they still had fewer proliferating cells, did not display
a significant difference relative to wild type littermate controls
(Figs. 5D–F). In animals 10 weeks of age or older, prostatic
organ-size was indistinguishable between Sfrp1 null animals
and wild type littermate controls. These data suggested that
Sfrp1 null animals undergo a developmental delay in which
puberty-associated cellular proliferation is temporally deferred,
but no long-term deficit in organ growth occurs. Sfrp1 null
prostates were also evaluated for changes in apoptosis using a
Terminal Deoxynucleotidyl Transferase–Mediated Nick-End
Labeling (TUNEL) assay. TUNEL-positive apoptotic cells were
extremely rare in wild type control prostates as has previously
been reported (Jara et al., 2004), and no increase in apoptotic
cells was observed in the prostates of Sfrp1 null mice (data not
shown).
Sfrp1 attenuates expression of genes encoding
androgen-regulated secretory proteins
To examine prostatic epithelial cell differentiation in Sfrp1
null mice, three genes encoding prostate-specific secretory pro-
teins with expression that is restricted to specific anatomical
lobes of the mouse prostate were examined: β-microsemiono-
protein (Msmb) (Ulvsback et al., 1991), spermine binding
protein (Sbp) (Chang et al., 1987) and tranglutaminase 4 (Tgm4)
(Dubbink et al., 1998). These markers were initially examined in
Sfrp1 null and littermate control prostates by in situ hybridiza-
tion showing that each marker maintained proper lobe-specific
localization in the Sfrp1 null prostates (data not shown). How-
ever, staining appeared more intense in the Sfrp1 null prostates
suggesting a possible increase in transcript levels. To evaluate
this possibility in amore quantitative way, real time RT-PCRwas
performed on RNA from Sfrp1 null prostates. Quantitative real
time RT-PCR analysis demonstrated that region-specific expres-
sion was spatially correct withMsmb detected in the ventral and
dorsolateral lobes (Fig. 6A), Sbp detected in the ventral lobesinuses from embryonic day 16.5 embryos were microdissected to separate the
esenchyme (UGM) and urogenital sinus epithelium (UGE) and analyzed by real-
expression were used evaluate the purity of the microdissected UGM and UGE.
relative to the UGE (A). Similarly, epithelial-specific gene cytokeratin19 was
similar to vimentin with most detectable transcripts in the UGM (C). All graphs
a control. Values are the average of 3 samples with the error bars depicting the
Fig. 4. Analysis of prostatic branching morphogenesis in Sfrp1 null mice. Prostates from both wild type (WT) littermate and Sfrp1 null (KO) animals were micro-
dissected at 5 weeks to reveal the ductal branching pattern as previously described (Sugimura et al., 1986). The mouse prostate contains pairs of anterior, dorsolateral,
and ventral lobes. Shown are the branching patterns for individual micro-dissected ventral prostate lobes from wild type (A–C) and Sfrp1 null (D–F) animals.
Photographs of the micro-dissected lobes are shown with (B, E) and without (A, D) a superimposed trace of the branched structure of the lobe. The traces are also
shown separately (C, F) with the ductal tips numbered to illustrate the greater number of ductal tips in the wild type lobe (42 ductal tips) relative to the Sfrp1 null lobe
(26 tips). Branching was quantified by counting the number of distal tips in each prostatic lobe under a microscope. The total average number of ductal tips present in
the anterior prostate (AP, total for the pair of anterior lobes), ventral prostate (VP, total for the pair of ventral lobes), and the dorsolateral prostate (DLP, total for the pair
of dorsolateral lobes) of wild type and Sfrp1 null mice are depicted in bar graphs (G). The Sfrp1 null animals demonstrated a reduction in branching morphogenesis in
each of the three prostatic lobes. The decrease in branching was statistically significant P-values from (ANOVAwith least significant difference post hoc analysis are
also indicated **P≤0.05, *P≤0.0001).
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lobes (Fig. 6C). In each case, expression was significantly in-
creased in Sfrp1 null mice relative to wild type littermate con-
trols. These data demonstrated that Sfrp1 negatively regulates
expression of these prostate-specific secretory proteins by lumi-
nal epithelial cells.
Over-expression of Sfrp1 in the prostate increases epithelial
proliferation and decreases expression of secretory genes
Prostatic epithelial proliferation and other cellular behaviors
aremodulated both by organ intrinsic signaling and by endocrine
signaling (Marker et al., 2003). To determine whether Sfrp1 can
modulate the behaviors of prostatic epithelial cells by acting
directly in the prostate, a prostate-specific Sfrp1 transgenic over-expression model (PB-SFRP1 mice) was created by placing a
full-length human SFRP1 cDNA under the control of androgen-
responsive, prostatic, epithelial-specific rat probasin promoter
(Zhang et al., 2000). This construct was used to make transgenic
mice using standard pronuclear injection techniques (see
Materials and methods). Three founder animals were identified
that carried the SFRP1 transgene construct. These animals were
bred to wild-type FVB/N animals and the resulting progeny were
screened by Southern blot to confirm germ line transmission of
the transgene (data not shown). Over-expression of SFRP1 in
the prostate of the transgenic mice was confirmed by immuno-
blotting (Fig. 7A). PB-SFRP1 mice from each transgenic line
were also examined for proliferation by IHC. Interestingly,
proliferating cells were still detected in the PB-SFRP1 prostates
at 5 months of age while the wild type littermate controls
Fig. 5. Loss of Sfrp1 delays puberty-associated proliferation in the mouse prostate. Immunostaining for Ki67 was used to examine proliferation in sections of wild type
littermate (A, D) and Sfrp1 null (B, E) prostates at 5 weeks of age (A, B) and 7 weeks of age (D, E). Proliferation was quantified by counting the number of luminal
epithelial cells expressing Ki67 in a total of 500 or more luminal epithelial cells per prostate lobe of each animal. A minimum of 3 animals was analyzed in each group.
At 5 weeks of age, Sfrp1 null prostates had significantly fewer proliferating cells than prostates from wild-type littermate controls (C). At 7 weeks of age the reduction
in the number of proliferating cells in Sfrp1 null mice relative to controls was not as great and was not statistically significant (F). Statistically significant differences
from ANOVAwith least significant post hoc analysis are indicated on the graphs (**P≤0.05, *P≤0.0001).
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support the hypothesis that SFRP1 is acts as a pro-proliferation
signal by signaling locally in the prostate. Although PB-SFRP1
transgenic mice had increased proliferation in the adult prostate
gland, the histology of PB-SFRP1 remained normal at least to
1 year of age (Figs. 7E, F) with no evidence for an increased
incidence of epithelial hyperplasia or dysplasia relative to
controls.
Real time RT-PCR analysis for secretory gene expression was
also conducted for the PB-SFRP1 transgenic animals. Trans-
genic animals at 1 year of age demonstrated the same lobe-
restricted pattern of expression as 1-year-old wild type controls,
but each of the transcripts was decreased in expression in the
transgenic prostates relative to the controls (Fig. 7G). We did
detect a change in the lobar expression pattern forMsmb at the 1-
year time point relative to the younger mice (compare Fig. 7A to
Fig. 6A), but this change in pattern was seen in both the control
and transgenic mice. The effects of the PB-SFRP1 transgene on
the expression of Msmb, Sbp, and Tgm4 were also examined inFig. 6. Sfrp1 limits the expression levels of region-specific prostatic secretory pro
proteins with region-restricted expression by differentiated luminal epithelial cells in
compared in the Sfrp1 null prostates and wild type littermate controls using real-time
Msmb expression was increased in the ventral and dorsolateral prostates of Sfrp1 null
(B). Tgm4 expression was increased in anterior and dorsolateral prostatic lobes of S
significant post hoc analysis are indicated on the graphs (**P≤0.05, *P≤0.0001).12-week-oldmice with similar but less drastic changes including
statistically significant decreases in expression for Msmb in the
dorsolateral prostate, Sbp in the ventral prostate, and Tgm4 in
the dorsolateral prostate (data not shown). PB-SFRP1 transgenic
prostates were also evaluated for changes in apoptosis using a
TUNEL assay. TUNEL-positive apoptotic cells were extremely
rare in wild type control prostates as has previously been
reported (Jara et al., 2004), and no increase in apoptotic cells was
observed in the prostates of PB-SFRP1 transgenic mice (data not
shown).
Sfrp1 induces signaling via the non-canonical WNT/JNK
pathway in prostatic epithelial cells
Proliferation of BPH1 prostatic epithelial cells is stimulated
by SFRP1 (Joesting et al., 2005). Thus, this cell line can serve as
an in vitro model for at least one of the in vivo responses of
prostatic epithelial cells to SFRP1 that were observed in this
study. We used BPH1 cells to evaluate the mechanism of SFRP1teins. The genes Msmb, Sbp, and Tgm4 encode androgen-regulated secretory
the mouse prostate gland (Thielen et al., 2007). Expression of these genes was
RT-PCR and is shown as relative expression normalized to 18s ribosomal RNA.
mice (A). Sbp expression was increased in the ventral prostate of Sfrp1 null mice
frp1 null mice (C). Statistically significant differences from ANOVAwith least
Fig. 7. Forced expression of Sfrp1 in the adult prostate induces proliferation and suppresses secretory gene expression. To further clarify the potential role of Sfrp1 as a
local regulator of proliferation and gene expression in the prostate, a transgenic model (PB-SFRP1mice) was developed to over-express an Sfrp1 cDNA specifically in
the prostate under control of the ARR2PB promoter (Zhang et al., 2000). Immuno-blots with an anti-SFRP1 antibody confirmed robust over-expression of SFRP1 in
the VP and DLP (A). Longer exposures of immuno-blots also confirmed over-expression in the AP (data not shown). In the adult prostate (5 months of age shown),
wild type prostates exhibited almost no Ki67 positive cells (B) while a dramatic increase in the number of Ki67 positive cells was observed in PB-SFRP1 prostates (C,
D examples indicated by the arrows in panel C). Although PB-SFRP1mice had increased proliferation in the adult prostate, the histology of the prostates in PB-SFRP1
mice remained normal [compare the hematoxylin and eosin stained 1-year-old wild type dorsolateral prostate (E) to the 1-year-old PB-SFRP1 dorsolateral prostate (F)].
Expression of secretory genes was also examined in PB-SFRP1 animals relative to littermate controls (G, data from 1-year-old transgenic and control mice shown).
Msmb expression and Sbp expression were decreased in the ventral prostates of PB-SFRP1 transgenic mice. A similar trend of decreased Tgm4 expression was
observed in both the anterior and dorsolateral prostates of PB-SFRP1 transgenic mice. However, the differences in expression for Tgm4 between controls and PB-
SFRP1 animals did not reach statistical significance. Statistically significant differences from ANOVA with least significant post hoc analysis are indicated on the
graphs (**P≤0.05, *P≤0.0001).
169M.S. Joesting et al. / Developmental Biology 317 (2008) 161–173action by examining candidate signal transduction pathways
that might be affected by SFRP1. As a binding partner of WNT/
Fz proteins, SFRP1 could potentially affect one or more of the
known WNT signal transduction pathways. To evaluate effects
on the canonical WNT/β-catenin pathway, changes in the
localization of β-catenin and the expression levels of 2 target
genes were examined. There was no change in β-catenin
localization in cells that over-expressed SFRP1 (Fig. 8A), and
the transcript levels for two genes regulated by the canonical
WNT/β-catenin pathway, c-myc and cyclinD1, were also un-
changed (Fig. 8B). At least two non-canonical pathways have
also been implicated as mediators of WNT signaling including
one pathway that stimulates signaling through phosphorylation
of JNK, and a second pathway that has been shown to signalthrough the phosphorylation of CamKII (Pandur et al., 2002;
Widelitz, 2005). These pathways were also evaluated in cells
over-expressing SFRP1. There was no change in activation of
CamKII (Fig. 8C), but there was a statistically significant 3-fold
increase in the activation of JNK in cells that over-expressed
SFRP1 (Fig. 8D). This finding suggested that SFRP1 plays a
novel role in prostatic epithelial cells by activation of the non-
canonical WNT/JNK pathway.
The potential activation of JNK in the prostates of wild type,
Sfrp1 null, and PB-SFRP1 transgenic mice was also evaluated
using immuno-blotting with an anti-phospho-JNK antibody. All
three genotypes had detectable levels of activated JNK in the
prostate (Fig. 8E). We attempted to use the anti-phospho-JNK
antibody in immunohistochemistry experiments to determine if
Fig. 8. SFRP1 over-expression induces a non-canonical WNTsignaling pathway. Non-tumorigenic prostatic epithelial BPH1 cells were stably transfected with a vector
expressing a human SFRP1 cDNA or with an empty vector to create a series of derivative cell lines including 3 derivative BPH1 cell lines stably transfected with an
empty vector (BPH1-IP2A, BPH1-IP2B, BPH1-IP2C), and 4 derivative BPH1 cell lines stably transfected with an SFRP1 expression cassette (BPH1-SFRP1A,
BPH1-SFRP1B, BPH1-SFRP1C, BPH1-SFRP1D). (A) Nuclear (N) and cytoplasmic (C) protein fractions were subjected to SDS-PAGE and immunoblotted for
activation of the canonical Wnt/β-catenin. No change in β-catenin localization was detected. Immunoblots for nuclear-specific PARP and cytoplasmic specific α/β-
tubulin were used as controls for the quality of protein fractions. (B) Real time RT-PCRwas used to look at transcriptional activation of β-catenin target genes c-Myc or
CyclinD1 with no changes detected. Whole cell extracts were also subjected to SDS-PAGE and immunoblotted for activation of non-canonical Wnt pathways. No
change in CamKII phosphorylation (P-CamKII) was detected in cells that over-expressed SFRP1 (C). A 3-fold increase in phosphorylated JNK (P-JNK) was detected
in cells that over-expressed SFRP1when compared to cells harboring empty vectors or the parental BPH1 cells (D). Immunoblots were quantified by densitometry and
activation was measured as a ratio of phosphorylated protein over total protein. The increase in P-JNK in response to SFRP1 over-expression was statistically
significant (*P≤0.0001). (E) Immunoblots also detected the presence of P-JNK in the prostates of Sfrp1 null (KO), wild type (WT), and PB-SFRP1 transgenic mice
(data shown is from 12-week-old mice).
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epithelial cells, and to determine if changing the levels of SFRP1
in the prostate altered the activation of JNK in prostatic epithelial
cells. Unfortunately, the anti-phospho-JNK antibody did not
detect a signal in immunohistochemistry experiments. Thus, we
cannot determine at this time whether the responses of JNK to
SFRP1 in cultured prostatic epithelial cells are also occurring in
the prostatic epithelial cells of SFRP1 transgenic or null mice.
Activation of the non-canonical WNT/JNK pathway mediates
the pro-proliferative response of prostatic epithelial cells to
SFRP1
The importance of JNK activation by SFRP1 was further
evaluated by testing the contribution of JNK activation to the
SFRP1-induced proliferation of prostatic epithelial cells. Theempty vector control and SFRP1 expressing cell lines evaluated
for signaling changes (Fig. 8) were also evaluated for proli-
feration in the presence or absence of SP600125 (Bennett et al.,
2001), a small molecule inhibitor of JNK (Fig. 9). Proliferation
was evaluated after 48 h of inhibitor treatment using immu-
nocytochemistry for proliferation-associated marker phospho-
(ser10)-histone H3. As previously observed (Joesting et al.,
2005), forced expression of SFRP1 caused a statistically signi-
ficant increase in the proliferation of BPH1 cells (Figs. 9A, C,
E). SP600125 had no effect on the proliferation rate of control
cells (Figs. 9A, B, E). However, SP600125 completely blocked
the increased proliferation induced by forced expression of
SFRP1 (Figs. 9C–E). These data showed that the SFRP1-
induced increase in proliferation required JNK, but JNK played
no detectable role in the proliferation of BPH1 cells in the ab-
sence of SFRP1.
Fig. 9. SFRP1-induced proliferation requires JNK activity. The same SFRP1-
expressing and empty vector control cells evaluated for signaling changes in Fig.
8 were also examined for changes in proliferation in response to SP600125
(Bennett et al., 2001), a small molecule inhibitor of JNK. Each treatment group
was assayed by immunocytochemistry for the proliferation-associated marker
phospho-(ser10)-histone H3. Treatments included empty vector cells treated
with vehicle only (A), empty vector cells treated with SP600125 (B), SFRP1-
expressing cells treated with vehicle only (C), and SFRP1-expressing cells
treated with SP600125 (D). Each of the 3 empty vector cell lines and the 4
SFRP1-expressing line was examined. For each cell line and treatment group,
the results were quantified by counting the number of phospho-(ser10)-histone
H3 positive cells and the total number of cells contained in 3 microscopic fields
(a minimum of 1500 total cells were counted for each cell line and treatment
group). These data were used to calculate the phospho-(ser10)-histone H3
labeling index as a measure of relative proliferation (E). No change in
proliferation was observed in empty vector harboring BPH1 cells when cultured
with the JNK inhibitor relative to vehicle controls. A statistically significant
(P≤0.0001) 2-fold increase in proliferation was observed in SFRP1-expressing
BPH1 cells compared to empty vector cells. This increase in proliferation in
response to SFRP1 was completely blocked by the JNK inhibitor such that
proliferation of inhibitor-treated SFRP1-expressing cells was statistically
indistinguishable from proliferation of empty vector control cells. The results
of two independent inhibitor experiments are shown as the two right bars. Error
bars depict the standard error. P-values were calculated using ANOVAwith least
significant difference post hoc analysis.
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Our initial interest in the role of SFRP1 in the prostate gland
came from an investigation of stromal-to-epithelial signaling
during prostate cancer progression. We identified SFRP1 as a
candidate paracrine pro-proliferative signal that was over-
expressed by fibroblasts isolated from prostatic adenocarcino-
mas relative to fibroblasts isolated from benign prostates (Joe-
sting et al., 2005). While our study on prostate cancer was in the
process of being published, a second study identified SFRP1 as a
gene that is epigentically silenced in prostatic epithelial cells
during cancer progression (Lodygin et al., 2005). Both our study
and the study by Lodygin et al. tested the affects of Sfrp1 on
cultured prostatic epithelial cell lines. We observed increased
proliferation of the BPH1 cell line in response to Sfrp1 over-
expression while Lodygin et al. observed decreased growth of
the PC-3 cell line in response to Sfrp1 over-expression. These
contrasting experiments using different cell lines suggested that
the cellular context had a large impact on the response to SFRP1
in prostatic epithelial cells. These results also created uncertainty
as to the potential biological role SFRP1 in the context of normal
prostatic development.
Differential response to SFRP1 by different cell lines might
be expected because SFRP1 acts by binding WNT ligands and/
or Frizzled receptors (Fz) to modulate signaling, and the po-
tential complexity of signaling is high due to the multiple SFRP,
WNT, and Fz genes present in mammalian genomes. SFRP1 is
one of five SFRPs identified in mice and humans. In addition,
mice and humans have 19 different WNT ligands and 10 dif-
ferent frizzled receptors. Evidence suggests that the numerous
possible ligand/receptor combinations, including SFRP/WNT
and SFRP/Fz interactions, could preferentially and specifically
determine target gene activation by inducing different signaling
pathways (Rodriguez et al., 2005; Widelitz, 2005). This po-
tential complexity together with the contrasting in vitro results
with different prostate cell lines created a need to evaluate the
status and functional roles of Sfrp1 in vivo in the normal
prostate.
Our previous study used real time RT-PCR to show that the
normal in vivo expression of Sfrp1 in the mouse is relatively
high during prostatic development and low in the adult prostate
(Joesting et al., 2005). We also previously examined Sfrp1
expression in the postnatal day 1 rat ventral prostate by in situ
hybridization and observed expression in both the developing
mesenchyme and epithelium (Joesting et al., 2005). For the
current study, we attempted to detect mouse Sfrp1 transcripts at
several points during mouse prostatic development by in situ
hybridization using antisense RNA experimental probes and
sense strand RNA probes as a negative control. Although several
probes were tried, the signal for experimental probes did not
significantly exceed the signal for sense control probes sug-
gesting that this technique was not sufficiently sensitive to detect
the Sfrp1 transcripts that were detectable in the mouse prostate
by RT-PCR. As an alternative approach, the lacZ gene expressed
from the Sfrp1lacZ knock-in allele as a reporter for the expression
pattern created by endogenous Sfrp1 regulatory elements were
used (Fig. 2). This reporter recapitulated previously described
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tion at several developmental time points (Leimeister et al.,
1998). Within the prostate, the reporter was primarily expressed
in the developing mesenchyme/stroma across multiple devel-
opmental stages from p1 to p21. At some developmental stages,
β-galactosidase activity was also observed in limited regions of
the prostatic epithelium of Sfrp1lacZ heterozygous mice, but
similar staining was observed in wild type control embryos at
the same stages. Because we did observe epithelial Sfrp1
transcripts by in situ hybridization in the postnatal day 1 rat
ventral prostate (Joesting et al., 2005), some of the epithelial
staining may have reflected the activity of the endogenous
Sfrp1 regulatory elements, but the background observed in
negative controls prevented us from reaching definitive
conclusions regarding epithelial expression. Nevertheless, the
expression β-galactosidase reporter observed in the developing
mesenchyme was much more extensive than the observed
epithelial staining, and real-time RT-PCR of separated UGM
and UGE confirmed a predominantly mesenchymal expression
for Sfrp1 in the mouse prostate (Fig. 3).
To address how normal and ectopic Sfrp1 expression affects
the prostate in vivo, we employed both loss- and gain-of-
function mouse genetic models. Our analyses of these models
demonstrated several developmental defects in the prostates of
Sfrp1 null animals. In addition, complementary changes in pro-
liferation and androgen-dependent secretory gene expression
were observed in the Sfrp1 null mice and the PB-SFRP1 trans-
genic over-expression model. Interestingly, the developmental
defects in Sfrp1 null mice were primarily epithelial defects
although Sfrp1 appears to be mainly expressed in the developing
mesenchyme/stroma. This makes SFRP1 another potential me-
diator of the mesenchyme/stroma-to-epithelial paracrine signals
that have been inferred from previous genetic and experimental
embryological studies (Marker et al., 2003). Other mesenchy-
mally-expressed paracrine signals that modulate the develop-
ment of the prostatic epithelium include FGF10 that stimulates
growth and branching morphogenesis (Donjacour et al., 2003),
and BMP4 and BMP7 that inhibit prostatic branching morpho-
genesis (Grishina et al., 2005; Lamm et al., 2001). The pheno-
types present in Sfrp1 null mice are distinct from the phenotypes
reported for Fgf10, Bmp4, or Bmp7 mutants. In particular, the
increased expression of several androgen-dependent secretory
genes (Fig. 7) in Sfrp1 null mice is a unique phenotype that has
not previously been associated with defects in other paracrine
signaling pathways in the prostate. Expression of these genes
normally occurs as luminal prostatic epithelial cells complete
development and differentiate into growth quiescent secretory
cells. The phenotypes of prostates with loss and gain of Sfrp1
activity suggest that Sfrp1 antagonizes differentiation while
simultaneously promoting proliferation. Other genes including
Nkx3.1 are known to have an opposite role in the prostate and
promote differentiation while simultaneously limiting prolifera-
tion (Bhatia-Gaur et al., 1999).
Although Sfrp1 appears to have some unique roles in pros-
tatic development, it may also cooperate with other paracrine
signaling pathways. Little is currently known about the roles of
WNT signaling during prostatic development, but data fromother branched organs supports the idea that WNT pathways
cooperate with other signaling systems. The canonical WNT/β-
catenin was shown to act upstream of both FGF and BMP4
signaling as a negative regulator of lung branching morphogen-
esis (Dean et al., 2005; Shu et al., 2005) although others
reported that inhibition of β-catenin signaling by the Wnt
antagonist Dickkopf-1 disrupted branching in the lung (De
Langhe et al., 2005). WNT4 signaling was shown to be
involved in mammary duct branching during both puberty and
pregnancy (Brisken et al., 2000). Our data show that SFRP1, a
secreted modulator of WNT signaling, is important for several
aspects of prostatic development. One important goal of future
research will be to determine how SFRP1 interacts with the FGF
and BMP signaling pathways that have previously been
implicated as important paracine modulators of prostatic
development.
Another interesting finding in this study relates to the role of
Sfrp1 in WNT signaling. Almost no data have been published
on the potential role of WNT signaling during prostatic deve-
lopment. One recent publication does state that WNT5a, a
noncanonical WNT, is a mesenchymal inhibitor of prostatic
development, but this assertion was based on currently un-
published data (Pu et al., 2007). More data have been published
regarding the potential role of WNTsignaling in prostate cancer.
Many cancer types exhibit over-activation of the canonical
WNT/β-catenin signaling pathway. Studies of WNT/β-catenin
signaling in prostate cancer have reported a variety of results
that have been summarized in a recent review by Yardy and
Brewster (2005), and the importance of changes in canonical
WNT signaling in prostate cancer is still debated. Our previous
study found that prostatic epithelial cells exposed to recom-
binant SFRP1 at least transiently down-regulated expression
from a reporter plasmid for canonical WNT signaling, and sus-
tained expression of Sfrp1 in the same cells caused a sustained
increase in proliferation rate for the cells (Joesting et al.,
2005).
In the present study, we sought to further clarify the
mechanism of Sfrp1-induced proliferation of prostatic epithelial
cells by examining both canonical and non-canonical WNT
pathways for sustained changes in response to a continuous
Sfrp1 signal. We did not observe sustained changes in the
level of nuclear β-catenin or the expression of downstream
targets of canonical WNT signaling in response to sustained
Sfrp1 over-expression (Fig. 8). There was a significant amount
of nuclear β-catenin in the prostatic epithelial cells so β-catenin
potentially contributed to proliferation of the cells, but any such
role for β-catenin appeared to be independent of regulation by
Sfrp1. Cells that over-expressed Sfrp1 were also analyzed for
activation of the non-canonical WNT/JNK pathway and for
activation of the calcium pathway through phosphorylation of
CamKII. We found that Sfrp1 over-expression led to a
sustained activation of the non-canonical WNT/JNK pathway,
and that activation of this pathway was essential for Sfrp1-
induced proliferation of prostatic epithelial cells. This finding
represents a novel function for the non-canonical WNT/JNK
pathway as a regulator of prostatic epithelial cells downstream
of Sfrp1.
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